Thakur Purnima, Aggarwal Vineet, Gupta Manish, Azad Anjali, Negi Naina, Verma Vishal, Sharma Parul, Parihar Neeraj
Department of Radiotherapy, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
Department of Orthopedics, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
J Contemp Brachytherapy. 2024 Oct;16(5):362-370. doi: 10.5114/jcb.2024.144816. Epub 2024 Oct 31.
Soft tissue sarcomas (STS) due to their aggressive nature, pose challenges in achieving optimal local control (LC) rates following surgery. Brachytherapy offers precise delivery of high radiation doses to target tissues, potentially enhancing LC rates. This feasibility study explored the efficacy of perioperative high-dose-rate brachytherapy (PHDRB) and external beam radiation therapy (EBRT) in improving LC rates for STS, with a particular focus on interstitial brachytherapy and dose escalation strategies for high-risk patient sub-groups.
Seven patients with STS underwent conservative surgery and PHDRB between October 2020 and October 2023. PHDRB doses ranged from 3.0 to 3.5 Gy BID in 10 fractions, with or without subsequent EBRT, as indicated. EBRT was delivered in 4-5 weeks after surgical procedure at a dose of 45-50 Gy in 25 treatments, with daily dose of 1.8-2.0 Gy. Brachytherapy techniques and dosimetry guidelines were meticulously implemented to ensure optimal treatment delivery and minimize toxicity.
All seven patients tolerated treatment well without acute or late radiation-related complications. Excellent local disease control was achieved in all cases, but three patients developed distant metastases. The overall feasibility and efficacy of PHDRB in combination with EBRT were promising.
This study underscores the feasibility and potential efficacy of PHDRB and EBRT for STS treatment. Despite limitations in sample size, the results are promising, warranting further investigation through multi-centric studies. The use of dose-escalated PHDRB in high-risk cases enabled more intensive treatment delivery directly to the tumor bed, which may be critical for enhancing local control in patients with aggressive or large tumors. In facilities with limited resources and a high patient burden, where conformal radiotherapy is unavailable, brachytherapy remains an excellent modality for boosting the tumor bed or serving as a radical radiotherapy treatment.
软组织肉瘤(STS)因其侵袭性,在术后实现最佳局部控制(LC)率方面面临挑战。近距离放射治疗可将高剂量辐射精确地传递至靶组织,有可能提高LC率。本可行性研究探讨了围手术期高剂量率近距离放射治疗(PHDRB)和外照射放疗(EBRT)在提高STS的LC率方面的疗效,特别关注间质近距离放射治疗以及高危患者亚组的剂量递增策略。
2020年10月至2023年10月期间,7例STS患者接受了保肢手术和PHDRB。PHDRB剂量为3.0至3.5 Gy,每日两次,分10次给予,视情况加或不加后续EBRT。EBRT在手术后4 - 5周进行,剂量为45 - 50 Gy,分25次给予,每日剂量为1.8 - 2.0 Gy。严格执行近距离放射治疗技术和剂量测定指南,以确保最佳治疗实施并将毒性降至最低。
所有7例患者对治疗耐受性良好,无急性或晚期放疗相关并发症。所有病例均实现了良好的局部疾病控制,但3例患者出现远处转移。PHDRB联合EBRT的总体可行性和疗效令人鼓舞。
本研究强调了PHDRB和EBRT用于STS治疗的可行性和潜在疗效。尽管样本量有限,但结果令人鼓舞,值得通过多中心研究进一步探究。在高危病例中使用剂量递增的PHDRB能够将更强化的治疗直接传递至肿瘤床,这对于增强侵袭性或大肿瘤患者的局部控制可能至关重要。在资源有限且患者负担重、无法进行适形放疗的机构中,近距离放射治疗仍然是增强肿瘤床剂量或作为根治性放疗的一种出色方式。